Few industry executives believe the settlement of litigation between independent pharmacists and drug cpompanies itself will change company pricing practices; if anything, the court emphatically affirmed that differential pricing supports, rather than undermines, a competitive marketplace.
You may also be interested in...
HHS Secretary Azar explains why companies have not voluntarily lowered prices as yet, despite President Trump’s recent comments. He also discussed using regulations to prohibit rebates.
US FDA Commissioner Gottlieb suggests administrative action to prohibit drug rebates as a way to lower drug prices. His remarks may preview an upcoming proposal from President Trump and HHS Secretary Azar.
The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.